Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,472
Recruiting: 1,283
Ph III recruiting: 130
Growth YoY: +4.1%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,642)

clinicaltrialsPublishedShowing 301–350 of 711 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05976997	Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)	recruiting	Phase 2	36	Liling ZhangOTHER	1	May 18, 2026	clinicaltrials
NCT06005870	Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression	recruiting	Phase 2	41	Huazhong University of Science and TechnologyOTHER	1	May 18, 2026